Home

We anticipate that this topical treatment will increase genital sensitivity in women, facilitating sexual arousal and helping treat sexual dysfunction. Background:
As the population ages, there has been increased focus around sexual dysfunction as a medical issue. This has resulted in a number of successful treatments that ameliorate sexual dysfunction in men. However, treatments aimed at woman have not been nearly as effective. One of the reasons for this is that female sexual dysfunction is complex. At least one likely factor contributing to female dysfunction is diminished genital sensitivity arising from loss of sensory nerve fibers in the clitoris and vagina.Technology Overview:  
This technology is based on the hypothesis that topical 4-aminopyridine (4-AP) may enhance the sensitivity of the sensory nerves in the genital region and increase female sexual arousal. This medication has already been approved for oral use to improve neuronal function in conditions where either peripheral nerves or central neurons have impaired transmitter release or defective axonal conduction. We believe that 4-AP’s ability to prolong action potentials and facilitate the repetitive firing of neurons will allow it to be used topically as a treatment for sexual dysfunction. https://suny.technologypublisher.com/files/sites/adobestock_5878419381.jpegAdvantages:  
•    Easy and safe topical application
•    Uses medication that has already been approved for a different purpose. Applications:  
The primary use for this technology is for treatment of female sexual dysfunction. Intellectual Property Summary:
Patent Issued: US10888552B2, “Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability” (see also https://patents.google.com/patent/US10888552B2/en). Stage of Development:
TRL 2, Technology concept and/or application formulated.Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the treatment of female sexual dysfunction, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Health care providers.
•    Medical research laboratories.

This technology enables rapid, non-invasive detection and differentiation of all four dengue virus serotypes using saliva samples, with advanced qPCR and RT-LAMP assays, making dengue diagnosis easier, faster, and more accessible without the need for blood draws. Background:
Dengue virus (DENV) is a major global health concern, with hundreds of millions of infections occurring annually, particularly in tropical and subtropical regions. Accurate and timely diagnosis is crucial for effective patient management and for controlling outbreaks, especially since infection with one DENV serotype can increase the risk of severe disease upon subsequent infection with a different serotype. Traditionally, DENV diagnostics have relied on blood-based methods, which require trained phlebotomists, specialized equipment, and can be invasive and uncomfortable for patients. This reliance on blood samples poses significant challenges in resource-limited settings, where access to healthcare infrastructure and skilled personnel may be limited, and where rapid, large-scale testing is often needed during outbreaks. Current diagnostic approaches for DENV, such as conventional PCR and serological tests, face several limitations. Blood-based PCR assays, while sensitive, often require complex sample preparation, including RNA purification, and are susceptible to inhibitors present in crude samples, which can compromise accuracy. Serological assays, on the other hand, may not reliably distinguish between DENV serotypes or between primary and secondary infections, leading to potential misdiagnosis. Furthermore, the need for cold chain storage, specialized reagents, and laboratory infrastructure restricts the deployment of these tests in field or point-of-care settings. These challenges highlight the need for more accessible, rapid, and non-invasive diagnostic solutions that can be implemented widely, particularly in outbreak-prone and resource-constrained environments.Technology Overview:  
This technology provides a rapid, non-invasive diagnostic solution for detecting and differentiating all four dengue virus (DENV) serotypes using saliva samples. It integrates two advanced nucleic acid testing methods: a multiplex quantitative PCR (qPCR) assay and a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. The multiplex qPCR can simultaneously identify DENV1–4 and a human internal control in under 90 minutes, with high sensitivity down to 3–5 viral RNA copies per microliter, and is compatible with both purified and crude saliva samples. The RT-LAMP assay, operating at a single temperature, delivers serotype-specific results in as little as 7–15 minutes and supports simple colorimetric or lateral-flow readouts, making it suitable for point-of-care settings. Both methods use standard commercial reagents and are designed for ease of use, eliminating the need for trained phlebotomists and enabling deployment in resource-limited environments. This technology is differentiated by its comprehensive approach to dengue diagnostics, leveraging large-scale genomic analysis to design highly specific primers and probes that ensure accurate serotype identification directly from saliva. Unlike traditional blood-based tests, this solution offers a non-invasive alternative that is easier to administer and more acceptable to patients, particularly in mass screening or pediatric contexts. The assays have been validated through rigorous human challenge studies and transcriptomic analyses, demonstrating comparable sensitivity and specificity to blood-based methods while also providing insights into host immune responses. Its compatibility with digital PCR and whole-genome sequencing further enhances its utility for research and epidemiological surveillance. The combination of rapid turnaround, high accuracy, non-invasive sampling, and adaptability to point-of-care use positions this technology as a significant advancement in global dengue management and public health diagnostics. https://suny.technologypublisher.com/files/sites/adobestock_349162542.jpegAdvantages:  
•    Non-invasive detection of all four Dengue virus serotypes using saliva samples, eliminating the need for blood draws.
•    Rapid results with multiplex qPCR providing detection in under 90 minutes and RT-LAMP assays delivering results within 7–15 minutes.
•    High sensitivity and specificity by targeting conserved, serotype-distinct genomic regions, with detection limits as low as ~3 copies/µL.
•    Compatibility with point-of-care settings due to tolerance of crude saliva inhibitors and use of standard commercial enzymes and reagents.
•    Supports multiple readout formats including fluorescent, colorimetric, and lateral-flow assays for flexible diagnostic use.
•    Enables viral RNA quantification and whole-genome sequencing directly from saliva, facilitating detailed viral analysis and surveillance.
•    Reduces reliance on trained medical personnel and specialized equipment, improving accessibility in resource-limited environments.
•    Potential to enhance understanding of host immune responses through saliva transcriptomic analysis alongside viral detection. Applications:  
•    Point-of-care dengue screening
•    Rapid outbreak surveillance
•    At-home dengue self-testing
•    Clinical trial participant monitoring
•    Travel health screening Intellectual Property Summary:
Patent application filed: 63/924,381, filed on 11/24/2025
Know-how basedStage of Development:
Design of highly specific primers and probes in hand, that ensure accurate serotype identification directly from saliva. TRL level 4.Licensing Status:
This technology is available for licensing.
 

Novel tools that promote the delivery of therapeutics to treat inner retinal diseases such as diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa.  Background:
Non-surgical access to tissues for direct biological manipulation, e.g. gene transfer, stem cell transplantation, and drug delivery, can be difficult because many tissues and organs are surrounded with, and protected by, a nearly impenetrable barrier called the basement membrane (BM). In the eye, the inner limiting membrane (ILM) is a special BM that prevents movement into the retina from the vitreous. Current methods to circumvent the ILM involve its physical or enzymatic removal and have limited efficacy. As a result, successful cell- and gene- based therapies have targeted a subretinal approach, which has proven effective for the outer retina, but is of extremely limited use for the inner retina. Technology Overview:  
This technology describes the use of Ntn4-based molecules to disrupt the laminin polymer needed to form the ILM, allowing for access to these otherwise inaccessible tissues, and for therapies based on that access. This approach is also applicable to a wide variety of other tissues that contain a basement membrane that block the delivery of therapeutic agents. Of particular interest are organs with hard-to-breach BMs, including the kidney glomerulus, cornea and lens capsule, and the dermal/epidermal junction of the skin. https://suny.technologypublisher.com/files/sites/adobestock_4964568011.jpegAdvantages:  
•    Provides non-surgical access to inner retinal tissues.
•    Promotes gene-based and cell-based therapeutics in inner retinal diseases.
•    Applicable to a wide variety of other tissues.  Applications:  
Manipulate the molecular structure of the ILM to promote integration of neural stem cells, viral transfection, or small molecule delivery for the treatment of diabetic retinopathy, retinal vein occlusion, and retinitis pigmentosa and other inner retinal diseases. Intellectual Property Summary: Provisional patent application filed: 63/709,982Stage of Development:
TRL 3 – Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to entities involved in gene therapy, stem cell therapy, and targeted drug delivery. Potential licensees include biopharmaceutical companies, ophthalmology-focused biotech firms, regenerative medicine developers, and platform technology companies seeking to enhance delivery of biologics or cell-based therapies across tissue barriers

This technology uses specially designed sulfonium lipid nanoparticles to deliver mRNA directly to lung cells through the nose, offering a non-invasive, more effective and targeted treatment for pulmonary diseases like asthma and cystic fibrosis. Background:
The field of pulmonary medicine faces significant challenges in the treatment of diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome, all of which involve complex interactions between lung epithelial and immune cells. Advances in genetic medicine, particularly messenger RNA (mRNA) therapeutics, have opened new avenues for treating these conditions by enabling the direct modulation of gene expression within target cells. However, the success of mRNA-based therapies hinges on the ability to deliver these fragile molecules efficiently and specifically to the relevant lung cells. Intranasal administration is a promising route due to its non-invasiveness and direct access to the respiratory tract, but it requires delivery systems that can protect mRNA from degradation and ensure its uptake by the desired cell types. Current approaches to mRNA delivery, such as conventional lipid nanoparticles, face several limitations when applied to pulmonary diseases. These formulations often lack the specificity needed to target lung epithelial and immune cells, resulting in suboptimal therapeutic outcomes and potential off-target effects. Furthermore, many existing nanoparticles struggle to traverse the mucus barrier and are rapidly cleared from the respiratory tract, reducing the amount of mRNA that reaches the intended cells. Inefficient encapsulation and delivery can also lead to degradation of the mRNA payload before it exerts its therapeutic effect. As a result, there is a pressing need for more effective and targeted delivery vehicles that can overcome these biological barriers and improve the efficacy of mRNA-based treatments for lung diseases.Technology Overview:  
This technology introduces a new class of sulfonium lipid nanoparticles specifically engineered for the intranasal delivery of mRNA molecules to lung epithelial and immune cells. These nanoparticles are carefully designed and synthesized to encapsulate and protect mRNA, ensuring efficient transport and localized release within the lungs. By optimizing the formulation, the technology achieves superior performance compared to existing lipid-based delivery systems, providing enhanced targeting and uptake by the intended lung cell populations. The system is designed to address the longstanding challenge of delivering genetic material directly to the respiratory tract, which is crucial for treating pulmonary diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome. What differentiates this technology is its unique chemical structure and formulation, which enable highly specific and efficient delivery of mRNA to lung cells via the intranasal route. Unlike conventional lipid nanoparticles, the sulfonium-based design offers improved stability, cellular uptake, and targeting capabilities, resulting in higher therapeutic efficacy and reduced off-target effects. The technology fills a critical gap in the market by providing a non-invasive, localized delivery method that can be readily adapted for a variety of mRNA-based therapeutics. Its development, supported by NIH funding and validated through rigorous experimentation and peer-reviewed disclosure, positions it as a leading solution for advancing pulmonary drug delivery and gene therapy. https://suny.technologypublisher.com/files/sites/adobestock_1237485827.jpegAdvantages:  
•    Enables targeted and efficient intranasal delivery of mRNA to lung epithelial and immune cells
•    Optimized sulfonium lipid nanoparticles outperform existing benchmark lipid formulations for mRNA delivery
•    Facilitates localized gene expression critical for treating pulmonary diseases such as cystic fibrosis, asthma, and acute respiratory distress syndrome
•    Non-invasive administration route through intranasal delivery improves patient compliance
•    Supports development of novel mRNA-based therapeutics for a wide range of lung diseases
•    Innovative chemical design avoids reliance on existing intellectual property, allowing for broad application and further development Applications:  
•    mRNA therapeutics for cystic fibrosis
•    Asthma gene therapy delivery
•    Acute respiratory distress treatment
•    Targeted lung cancer mRNA therapy
•    Vaccines for respiratory infections Intellectual Property Summary:
Patent application: 63/783,376, filed on 4/4/2025
Issued patent
Know-how based
CopyrightStage of Development:
TRL 3 
Sulfonium lipid nanoparticles are specifically engineered for the intranasal delivery of mRNA molecules to lung epithelial and immune cells Licensing Status:
This technology is available for licensing.